Search Results for "warfarin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for warfarin. Results 31 to 38 of 38 total matches.
See also: Coumadin

Drugs for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
of warfarin. Hepatic enzyme-inducing ASMs (including carbamazepine, phenytoin, and phenobarbital) can reduce ...
When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of use, spectrum of activity, adverse effects, interactions with other drugs, presence of comorbid conditions, suitability for elderly persons and those with childbearing potential, and cost. Treatment should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8   doi:10.58347/tml.2024.1708a |  Show IntroductionHide Introduction

Drugs for Alcohol Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021  (Issue 1639)
the anticoagulant effect of warfarin and raise serum concentrations of phenytoin. OFF-LABEL ALTERNATIVES ...
Consumption of alcohol has increased during the COVID-19 pandemic. The Diagnostic and Statistical Manual for Mental Disorders, 5th edition (DSM-5) defines alcohol use disorder (AUD; previously called alcohol dependence) as meeting ≥2 of the 11 criteria listed in Table 1 in the past year. The lifetime prevalence of AUD in the US population has been estimated to be about 30%. Despite this high prevalence and the associated morbidity, mortality, and costs, only 3 drugs are FDA-approved for treatment of the disorder.
Med Lett Drugs Ther. 2021 Dec 13;63(1639):193-8 |  Show IntroductionHide Introduction

Drugs for Gout

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
may increase the INR in patients taking warfarin. Patients taking aspirin for cardiovascular protection ...
Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75   doi:10.58347/tml.2023.1688a |  Show IntroductionHide Introduction

Drugs for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021  (Issue 1620)
– Teriflunomide can decrease serum concentrations of warfarin and of CYP1A2 substrates. It can increase serum ...
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
Med Lett Drugs Ther. 2021 Mar 22;63(1620):42-8 |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
of leflunomide. Teriflunomide may decrease the anticoagulant effect of warfarin. Use of leflunomide with oral ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction

Drugs for Plaque Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
indices such as warfarin or cyclosporine may be needed. According to the The Medical Letter ® Vol. 66 ...
Mild to moderate plaque psoriasis can be treated with topical drugs and phototherapy. Patients with moderate to severe disease generally require systemic therapy. Guidelines for the treatment of psoriasis with topical therapy, phototherapy, and systemic drugs have recently been published.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):153-60   doi:10.58347/tml.2024.1712a |  Show IntroductionHide Introduction

Drugs and Devices for Weight Management

   
The Medical Letter on Drugs and Therapeutics • May 30, 2022  (Issue 1651)
; patients on stable doses of warfarin or other anticoagulants should be monitored for changes ...
Adults with a body mass index (BMI) between 25 and 29.9 kg/m2 are considered overweight. Those with a BMI ≥30 are considered obese. The initial recommendation for any weight loss effort is to achieve a 5-10% reduction in weight, which has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the preferred methods for losing weight, but long-term weight maintenance can be difficult. Several drugs and devices are FDA-approved for weight reduction and maintenance of weight...
Med Lett Drugs Ther. 2022 May 30;64(1651):81-8 |  Show IntroductionHide Introduction

Drugs for Irritable Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025  (Issue 1721)
Changes in the INR have been reported in patients taking warfarin and rifaximin concurrently. BILE ACID ...
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating. IBS is classified by its predominant bowel symptom: constipation (IBS-C), diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Since the exact cause of IBS is unknown, the goal of treatment is symptom control. Some over-the-counter (OTC) products and prescription drugs for IBS are listed in Tables 1-4. The safety of these drugs during pregnancy and lactation is described in Table 5 (online only).
Med Lett Drugs Ther. 2025 Feb 3;67(1721):17-24   doi:10.58347/tml.2025.1721a |  Show IntroductionHide Introduction